- Home
- INKT vs IGC Comparison
INKT vs IGC Comparison
Compare INKT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- IGC
- Stock Information
- Founded
- INKT 2017
- IGC 2005
- Country
- INKT United States
- IGC United States
- Employees
- INKT N/A
- IGC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- IGC Health Care
- Exchange
- INKT Nasdaq
- IGC Nasdaq
- Market Cap
- INKT 36.7M
- IGC 29.4M
- IPO Year
- INKT 2021
- IGC N/A
- Fundamental
- Price
- INKT $10.10
- IGC $0.30
- Analyst Decision
- INKT Strong Buy
- IGC Strong Buy
- Analyst Count
- INKT 2
- IGC 2
- Target Price
- INKT $6.50
- IGC $3.75
- AVG Volume (30 Days)
- INKT 70.0K
- IGC 399.9K
- Earning Date
- INKT 03-20-2025
- IGC 03-04-2025
- Dividend Yield
- INKT N/A
- IGC N/A
- EPS Growth
- INKT N/A
- IGC N/A
- EPS
- INKT N/A
- IGC N/A
- Revenue
- INKT N/A
- IGC $1,236,000.00
- Revenue This Year
- INKT N/A
- IGC N/A
- Revenue Next Year
- INKT N/A
- IGC $13.38
- P/E Ratio
- INKT N/A
- IGC N/A
- Revenue Growth
- INKT N/A
- IGC 1.64
- 52 Week Low
- INKT $4.56
- IGC $0.27
- 52 Week High
- INKT $19.00
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- INKT 54.73
- IGC 38.51
- Support Level
- INKT $8.97
- IGC $0.29
- Resistance Level
- INKT $9.98
- IGC $0.33
- Average True Range (ATR)
- INKT 1.44
- IGC 0.01
- MACD
- INKT -0.07
- IGC -0.00
- Stochastic Oscillator
- INKT 42.97
- IGC 15.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.